Baliga told CNBC-TV18, "In midcaps pharma most of them have already moved up decently well. So at this point of time, we are suggesting people to start buying Dr Reddy's, which hasn't done too well in the recent past, but then looking at the next two year's story, we feel that a stock like Dr Reddy's should easily give you 30-35% return per annum."